Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
View Full LandscapeTarget Indication
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Clinical Trial
NCT05445843Last updated: 2/14/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.